和铂医药-B尾盘涨超5%,因将公布普鲁苏拜单抗临床数据,并推进HBM7020在自免领域合作,该药物已授权大冢制药与华兰生物。
Source Link和铂医药-B尾盘涨超5%,因将公布普鲁苏拜单抗临床数据,并推进HBM7020在自免领域合作,该药物已授权大冢制药与华兰生物。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.